clinical trial · NCT06196905
An Exploratory Study of MT-2990 in Patients With AAV
Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)MT-2990
brief summary
To explore the efficacy, safety, pharmacokinetics and mechanism of action of MT-2990 in patients with AAV.
started
Jun 24, 2024
primary completion
Jan 14, 2026
completion
Jan 14, 2026
last updated
Feb 4, 2026
detailed description
Target sample size is 5\~10 subjects administered MT-2990
official title
An Exploratory Study of MT-2990 in Patients With Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol